September 12, 2017
Astellas Pharma said on September 11 that it has submitted an application in Japan seeking an additional indication of chronic constipation for its guanylate cyclase-C receptor agonist Linzess (linaclotide). Linzess, which was licensed from US partner Ironwood Pharmaceuticals, was approved...read more